links for 2009-10-23

By MaverickNY on October 23, 2009

Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation

The overall response rate, to date, is 65 percent (20/31 patients [95 percent CI: 45 percent, 81 percent]) and disease control rate (DCR) at 8 weeks is 84 percent (26/31 patients [95 percent CI: 66 percent, 95 percent]). Median PFS has not yet been reached. The median duration of treatment is 24.5+ weeks.

(tags: PF-02341066 c-MET ELM4-ALK NSCLC mutations Pfizer)
The FINANCIAL – Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In NSCLC Patients With Specific Gene

PF-02341066 is an investigational, selective, ATP-competitive small molecule dual inhibitor of mesenchymal epithelial transition growth factor (c-Met or hepatocyte growth factor) and ALK tyrosine kinases, which are implicated in the progression of several cancers, including NSCLC. A subset of NSCLC patients have been identified whose tumors carry a unique mutation in which the echinoderm microtubule-associated protein-like 4 (EML4) gene is fused to ALK, also known as an EML4-ALK translocation.

(tags: PF-02341066 c-MET ELM4-ALK mutations NSCLC Pfizer)